Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC

Immunohistochemical assays for programmed cell death ligand 1 (PD-L1) expression in non–small cell lung cancer (NSCLC) are either required or recommended to guide therapy with immune checkpoint inhibitors. Four commercially available immunohistochemical assays are currently available as either compl